Nama's AI scorecard currently rates DexCom Strong Buy (8.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is DXCM's P/E ratio?

DexCom trades at a trailing price-to-earnings ratio of 29.7.

When does DXCM report earnings?

DexCom's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $0.72.

What is the DXCM price target?

The median analyst price target from 26 analysts is $96.50, with a range of $79.00 – $120.00.

Is DXCM Shariah compliant?

Nama's AAOIFI-style screen reads DexCom as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

DexCom (DXCM)

Healthcare · Medical Devices · NASDAQ

S&P 500Nasdaq-100

DexCom (DXCM) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $29.62B, a trailing price-to-earnings ratio of 29.7 and a free-cash-flow yield of 3.4%. Over the most recent reported fiscal year, revenue grew 15.6% and free cash flow per share grew 73.8%. Nama's AI scorecard rates it Strong Buy, 8.8 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Strong Buy · 8.8/10

The top band of the Fundamental Verdict (8.6–10). As of Nov 7, 2026.

Momentum

Leading · +45.3% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-51.8%

How far the last close sits under the highest price of the past five years.

Market cap	$29.62B
Trailing P/E	29.7
Price / book	11.7
Price / sales	5.8
FCF yield	3.4%
Dividend yield	—
Gross margin	63.4%
Operating margin	24.0%
Net margin	19.4%
Revenue growth (YoY)	+15.6%
Revenue growth (3-yr annual)	+17.0%
EPS growth (YoY)	+26.7%
FCF/share growth (YoY)	+73.8%
Beta	1.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

DXCM earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate $0.72). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$0.73	$0.67	+9.0%	$1.34B
Q2 2026	Jul 30, 2026	$0.70	$0.61	+14.8%	$1.31B
Q1 2026	Apr 30, 2026	$0.56	$0.47	+19.1%	$1.19B
Q4 2025	Feb 12, 2026	$0.68	$0.65	+4.6%	$1.26B

DXCM analyst price target

Median target $96.50 from 26 analysts, ranging $79.00 – $120.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
STE	STERIS	$24.60B	23.2

Explore live DXCM data on Nama Insights →

Recent Congressional trades

DexCom trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Jefferson Shreve	House	Sell	$15,001 - $50,000	Jun 22, 2025
Jefferson Shreve	House	Buy	$15,001 - $50,000	Jun 22, 2025
Rob Bresnahan	House	Buy	$1,001 - $15,000	Jun 9, 2025
Jefferson Shreve	House	Sell	$15,001 - $50,000	May 8, 2025
Rob Bresnahan	House	Sell	$1,001 - $15,000	Apr 28, 2025
Rob Bresnahan	House	Buy	$1,001 - $15,000	Mar 27, 2025
Kevin Hern	House	Sell	$50,001 - $100,000	Jan 15, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Oct 15, 2023
Josh Gottheimer	House	Sell	$1,001 - $15,000	Sep 16, 2023
Tina Smith	Senate	Sell	$250,001 - $500,000	—

DXCM FAQ

Is DXCM a buy?: Nama's AI scorecard currently rates DexCom Strong Buy (8.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is DXCM's P/E ratio?: DexCom trades at a trailing price-to-earnings ratio of 29.7.
When does DXCM report earnings?: DexCom's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $0.72.
What is the DXCM price target?: The median analyst price target from 26 analysts is $96.50, with a range of $79.00 – $120.00.
Is DXCM Shariah compliant?: Nama's AAOIFI-style screen reads DexCom as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.